Prevention & Epidemiology Committee

Leadership

Time/Location

Thursday, October 12, 2023 12:30 p.m. - 2:30 p.m. Room: Regency A (Ballroom Level, West Tower)

Agenda

Introduction

Welcome and Opening Comments: Marian Neuhouser and Banu Arun

Cancer Prevention Keynote Presentation

"Commonly used medication and its role in gynecologic cancer prevention" Dr. Britton Trabert, Associate Professor, University of Utah School of Medicine, Huntsman Cancer Institute

Patient Advocate update: Cheryl Jernigan

Active Studies

<u>\$1823</u>, "A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumors". Drs. C. Nichols and L. Nappi. Activated: 6/1/20.

<u>\$1904</u>, "Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice Among Women with Atypical Hyperplasia or Lobular Carcinoma In Situ – Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE)." Drs. K. Crew, R. Kukafka, et al. Activated 9/1/20.

Closed Studies

S0820, "A Double-Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III – Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)." Drs. J. Zell, P. Brown, M.P. Lance, et al. Activated: 3/1/13. Closed: 6/30/23.

Other Group Studies with SWOG Study Champions

CTSU A151804, "Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events." Dr. G. Lyman. Activated: 1/31/20.

CTSU A212102, "A Blinded Reference Set for Multicancer Early Detection Blood Tests." Dr. J. McGuinness. Activated: 8/1/22. CTSU EA1151, "Tomosynthesis Mammographic Imaging Screening Trial (TMIST)." Dr. B. Arun. SWOG Activated: 7/6/17.

CTSU/NHLBI-MDS, "The National Myelodysplastic Syndromes Natural History Study." Drs. D. Hill and C. Arana Yi. Activated: 4/5/16.

Concept Reviewed by Cancer Prevention Steering Committee

52311, Treatment Persistence with Alternate Doses of Exemestane or Tamoxifen among Postmenopausal Women with Atypical Hyperplasia, Lobular Carcinoma in situ or Hormone Receptor-Positive Ductal Carcinoma in situ. Dr. J. McGuinness.

Studies approved by triage to be submitted for federal funding

S2405, Pilot Study of Intraoperative Radiotherapy (IORT) versus
Observation for Postmenopausal Women with Low-Risk Ductal
Carcinoma In Situ (DCIS) after Breast Conserving Surgery." Dr. E. Connolly.
Expected to be submitted as U34 in October 2023.

Potential amendments to existing or completed studies

Amendment to S1007, "Effects of Chemoprevention and Adjuvant Endocrine Therapy on a Convolutional Neural Network-Based Breast Cancer Risk Model Using Mammographic Datasets from S0812 and S1007." Drs. K Crew, K. Kalinsky, R. Ha.

Amendment to S1904, "Application of a Convolutional Neural Network-Based Mammographic Evaluation to Refine Breast Cancer Risk Prediction and Assess Response to Breast Cancer Chemoprevention."

New Business/Open Discussion for new ideas



Prevention & Epidemiology Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	S0820	S1823	S1904	A211102	A212102	EA1151	EA2185	EA8184	NRGCC008
Ascension Providence Hospitals - Southfield	1	-	-	-	-	-	-	-	-
Ascension Via Christi Hospitals Wichita	12	-	-	-	-	-	-	-	-
Audie L Murphy VA Hospital	-	-	-	-	15	-	-	-	-
Banner MD Anderson Cancer Center	10	3	-	-	-	57	-	-	-
Banner University Medical Center - Tucson	-	11	-	-	-	-	-	-	-
Baptist Memorial Health Care/Mid South Minority Underserved	4	-	3	-	-	2	-	-	-
Bay Area Tumor Institute NCORP	1	6	-	-	-	-	-	-	-
Baylor College of Medicine/Duncan Comprehensive Cancer Center	-	-	-	-	-	-	2	-	4
Brooke Army Medical Center	1	-	-	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	191	-	-	-
Cancer Research Consortium of West Michigan NCORP	2	2	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	1	5	-	-	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	1	3	-	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	4	18	-	-	2	-	-	-
City of Hope Comprehensive Cancer Center	1	-	16	2	-	-	-	-	-
Columbia University Minority Underserved NCORP	1	-	29	1	-	-	-	-	-
Columbus NCI Community Oncology Research Program	6	8	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	4	-	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	1	-	-	-	-	-	-	-	-
Essentia Health NCI Community Oncology Research Program	5	5	-	-	-	100	-	-	-
Georgia Cares Minority Underserved NCORP	2	-	-	-	-	-	-	-	-
Georgia NCI Community Oncology Research Program	2	-	-	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	-	13	-	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	10	3	16	-	-	28	-	-	-
Heartland Cancer Research NCORP	2	14	8	-	-	-	-	-	-
Henry Ford Hospital	-	-	-	-	4	133	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	40	138	10	-	-	-	-	-	-
Lahey Hospital and Medical Center	-	-	3	-	-	-	-	-	-
Loma Linda University Medical Center	2	6	-	-	-	-	-	-	-
Loyola University Medical Center	2	-	3	-	-	-	-	-	-
Massachusetts Veterans Epidemiology Research and Information Cntr	3	-	-	-	5	-	8	-	-
Medical University of South Carolina Minority Underserved NCORP	-	-	-	-	-	4	-	-	-
Meharry Medical College	1	-	-	-	-	-	-	-	-
Memorial Hermann Texas Medical Center	-	-	-	-	-	8	-	-	-
Mercy Medical Center - Des Moines	1	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	12	-	-	-	-	-	-	-	-
MultiCare Tacoma General Hospital	2	-	-	-	-	-	-	-	-



Prevention & Epidemiology Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	S0820	S1823	S1904	A211102	A212102	EA1151	EA2185	EA8184	NRGCC008
NCORP of the Carolinas (Prisma Health NCORP)	-	11	-	-	-	460	-	-	-
Nevada Cancer Research Foundation NCORP	1	1	-	-	-	-	-	-	-
New Mexico Minority Underserved NCORP	2	10	-	-	-	-	-	-	-
Northwell Health NCORP	2	11	-	-	-	-	-	-	1
Ohio State University Comprehensive Cancer Center LAPS	-	7	-	-	-	-	-	-	-
Oregon Health and Science University	-	15	-	-	-	-	1	1	-
Pacific Cancer Research Consortium NCORP	2	-	-	-	-	-	-	-	-
Salem Hospital	-	3	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	3	2	-	-	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	33	3	-	-	5	-	-	-	-
UC San Diego Moores Cancer Center	-	21	-	-	-	-	-	-	-
UCLA / Jonsson Comprehensive Cancer Center	-	30	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	5	31	-	-	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	-	-	-	376	2	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	5	-	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	8	20	-	-	2	2	-	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	4	-	-	-	-	-	-	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-	-	9	-	-	-
University of Mississippi Medical Center	1	6	-	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	7	-	-	-	-	-	-	-
University of Rochester LAPS	-	15	-	-	-	261	-	-	-
University of Texas Health Science Center at San Antonio	9	-	-	-	14	-	-	-	1
University of Texas MD Anderson Cancer Center LAPS	5	-	-	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	21	-	-	-	-	-	-
Upstate Carolina Consortium Community Oncology Research Program	-	-	-	-	-	619	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	6	-	-	-	-	-	-	-
Virginia Mason Medical Center	11	14	-	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	2	-	-	-	-	2	-	-	-
Western States Cancer Research NCORP	1	-	-	-	-	69	-	-	-
Wisconsin NCI Community Oncology Research Program	1	-	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	25	-	-	-	-	-	-	-	-
ALLIANCE	37	80	82	-	-	-	-	-	-
CCTG	-	148	-	-	-	-	-	-	-
ECOG-ACRIN	34	64	26	-	-	-	-	-	-
NRG	38	45	59	-	-	-	-	-	-
Total	354	776	294	3	45	2,323	13	1	6

